05 January 2024
05 January 2024
The FDA removes a partial clinical hold for Innate’s lacutamab trials following an investigation of a patient’s death.
The study met the primary endpoint at the interim assessment stage.
The company plans to commence a Phase II trial with subject screening anticipated to begin in the first half of this year.
Rhythm to acquire global rights for South Korean LG Chem’s oral obesity drug LB54640 for $100m in cash and equity.
The study is expected to commence subject enrolment in the first half of this year.
The studies enrolled 35 patients across various countries, with data scheduled for publication this year.
SpineX is planning to start recruitment for a pivotal trial in children with cerebral palsy in the first half of this year.
The trial met the primary and secondary endpoints of safety, tolerability and pharmacokinetics.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
